News und Analysen
3 Top Marijuana Stocks to Buy This Fall
Marijuana stocks weren't all that hot in the first half of 2017. The situation began to turn around for several leading marijuana stocks in the summer, though. What's the outlook for fall? Pretty....
Why Exelixis, Inc. Slumped Today
Exelixis (NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an analyst at Leerink Partners downgraded the biotech to market perform. Management also sold some shares, which could be contributing....
Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You?
Julian and Felix Baker of the $15.6 billion hedge fund Baker Bros. Advisors are well-known for their uncanny ability to unearth hidden gems in biotech and biopharma. So when I noticed that the....
Here's Why Arbutus Biopharma Corp. Stock Soared Today
Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) rode some mighty coattails today. This morning, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced highly positive data for a candidate that....
Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) is up more than 40% at 11:53 a.m. EDT after the company released positive phase 3 trial data for the Apollo trial testing its RNAi drug patisiran in patients....
What's Next for Alnylam Pharmaceuticals, Inc.?
The past 15 years haven't been easy for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shareholders. The company's new drug candidates are based on science that earned a Nobel Prize in 2006, but....
5 Marijuana Stocks Overflowing With Cash
Marijuana may be illegal at the federal level, but that hasn't slowed growth of the drug one iota within the U.S. or North America. In June, Mexico fully legalized medical cannabis, and right now....
Jeff Sessions May Soon Have a Green Light to Wage War on Medical-Marijuana Businesses
The U.S. marijuana industry has witnessed a number of major changes over the past two-plus decades. Since 1996, when California became the first state to legalize medical cannabis for....
Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?
Loxo Oncology (NASDAQ: LOXO) is one of biotech's best-performing stars this past year, and shares could still have room to run higher if the FDA cooperates with an OK for its lead drug,....
Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today
After Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced Thursday that it has crafted a new drug development platform, and created a handful of candidate compounds, shares of the clinical-stage....
Why Opko Health, Avis Budget Group, and Adomani Slumped Today
Thursday was another relatively quiet day for the stock market, and major benchmarks finished on either side of the unchanged mark by the end of the trading session. The Dow Jones Industrials hit....
Investors' Biggest Worry About GW Pharmaceuticals Could Be the Biotech's Ace in the Hole
GW Pharmaceuticals' (NASDAQ: GWPH) stock soared more than 60% last year. So far in 2017, though, shares of the cannabinoid-focused biotech are down rather than up. One possible reason behind GW....
Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy?
Shares of Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biotech, dropped by 13.69% today, after the company reported that its experimental treatment for super-refractory status epilepticus....
Masimo Corporation Fell 12.7% in August -- but Why?
Shares of Masimo Corporation (NASDAQ: MASI), a medical-device company focused on noninvasive testing equipment, fell by more than 12% in August, according to data from S&P Global Market....
Here's Why United Therapeutics Sank as Much as 10.8% Today
Shares of rare-disease specialist United Therapeutics (NASDAQ: UTHR) dropped nearly 11% today after the company announced that a phase 3 trial evaluating Orenitram in patients with pulmonary....
This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August
Shares of Valeant Pharmaceuticals (NYSE: VRX), a drugmaker that has predominantly grown via acquisitions over the years, plunged by 18% during August, according to data from S&P Global Market....
The 5 Worst Reasons to Buy Marijuana Stocks
Chances are you'd struggle to find an industry that's been stronger over the trailing one-year period than legal marijuana. Cannabis research firm ArcView pegged North American legal weed growth....
Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August
Editas Medicine (NASDAQ: EDIT) is researching the use of gene editing to treat disease. After the company updated investors on its progress on Aug. 9, shares soared 18.8% last month, according to....
Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) a clinical-stage biotech developing RNA-based therapies to treat rare diseases, announced an immediate halt to all studies with one of the....
Here's Why Cellectis SA Fell as Much as 31.6% Today
Shares of biopharma Cellectis (NASDAQ: CLLS) fell nearly 32% today after the company announced that the U.S. Food and Drug Administration had placed a clinical hold on its second leading product....
The 2 Major Catalysts Behind Myriad Genetics, Inc.'s 26% Gain in August
Shares of Myriad Genetics (NASDAQ: MYGN), a leading developer of molecular diagnostic tests, surged by 26% during the month of August, according to data from S&P Global Market Intelligence.....
We Got It Wrong With OPKO Health -- Now What?
In our "These Legendary CEO's Could Catch Lightning in a Bottle – Again" episode, Motley Fool Industry Focus: Healthcare contributor Todd Campbell picked OOKO Health (NASDAQ: OPK) as a stock to....
Here's Why Immunomedics Rose as Much as 14.2% Today
Shares of preclinical biopharma Immunomedics (NASDAQ: IMMU) gained over 14% today without any company-specific news. However, earlier in the day, the nearly $12 billion buyout of Kite Pharma by....
Say What? 2 New Studies Find Little Evidence That Marijuana Helps Treat Chronic Pain and PTSD
When it comes to growth industries, essentially nothing tops legal marijuana. According to cannabis research firm ArcView, the legal cannabis market in North America is slated to grow from $6.9....
Here's the Simple Issue I Still Have With Valeant Pharmaceuticals (and Why You Shouldn't Buy)
Over the past two years, only a small handful of publicly traded companies have the distinction of losing more than 90% of their value. Drugmaker Valeant Pharmaceuticals (NYSE: VRX) finds itself....